Changeflow GovPing Pharma & Drug Safety PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERI...
Routine Rule Added Final

PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The European Patent Office granted Patent EP3244930A1 to the University of Southern California on April 8, 2026. The patent covers pharmaceutical compositions comprising POH derivatives for therapeutic applications including cancer treatment. The patent is designated across 38 European member states including DE, FR, GB, IT, ES, NL, BE, and others.

What changed

The European Patent Office issued Patent EP3244930A1 to the University of Southern California, inventors Chen, Levin, and Pupalli, covering pharmaceutical compositions comprising POH derivatives. The patent is designated in 38 European states including Germany, France, United Kingdom, Italy, Spain, Netherlands, Belgium, Switzerland, Austria, Poland, Sweden, Denmark, Finland, Norway, Portugal, Greece, Czech Republic, Hungary, Romania, and others.\n\nGeneric pharmaceutical manufacturers and R&D companies developing POH-based therapeutics must consider this granted patent when planning market entry strategies in European designated states. Freedom-to-operate analyses and potential licensing negotiations may be necessary before commercializing similar compounds.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES

Publication EP3244930A1 Kind: A1 Apr 08, 2026

Applicants

University of Southern California

Inventors

CHEN, Thomas, LEVIN, Daniel, PUPALLI, Satish G.

IPC Classifications

A61K 31/415 20060101AFI20251120BHEP A61K 47/54 20170101ALI20251120BHEP A61K 47/55 20170101ALI20251120BHEP C07D 207/26 20060101ALI20251120BHEP A61K 31/4015 20060101ALI20251120BHEP C07D 487/04 20060101ALI20251120BHEP C07D 231/12 20060101ALI20251120BHEP A61N 5/10 20060101ALI20251120BHEP A61K 9/00 20060101ALI20251120BHEP A61K 45/06 20060101ALI20251120BHEP A61P 35/00 20060101ALI20251120BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3244930A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent examination IP licensing Drug development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!